Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management.
Olsson KM, Corte TJ, Kamp JC, Montani D, Nathan SD, Neubert L, Price LC, Kiely DG.
Lancet Respir Med. 2023 Sep;11(9):820-835. doi: 10.1016/S2213-2600(23)00259-X. Epub 2023 Aug 14.
Pulmonary hypertension in chronic lung disease and hypoxia.
Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W.
Eur Respir J. 2019 Jan 24;53(1):1801914. doi: 10.1183/13993003.01914-2018. Print 2019 Jan.
Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease.
Nathan SD.
Am J Respir Crit Care Med. 2023 Aug 1;208(3):238-246. doi: 10.1164/rccm.202212-2342CI.
Recent advances in the management of pulmonary hypertension with interstitial lung disease.
Waxman AB, Elia D, Adir Y, Humbert M, Harari S.
Eur Respir Rev. 2022 Jul 12;31(165):210220. doi: 10.1183/16000617.0220-2021. Print 2022 Sep 30.
Pulmonary Hypertension.
Hoeper MM, Ghofrani HA, Grünig E, Klose H, Olschewski H, Rosenkranz S.
Dtsch Arztebl Int. 2017 Feb 3;114(5):73-84. doi: 10.3238/arztebl.2017.0073.
Pulmonary hypertension in chronic lung diseases.
Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Vachiéry JL.
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036.
Pulmonary hypertension phenotypes in patients with systemic sclerosis.
Haque A, Kiely DG, Kovacs G, Thompson AAR, Condliffe R.
Eur Respir Rev. 2021 Aug 17;30(161):210053. doi: 10.1183/16000617.0053-2021. Print 2021 Sep 30.
Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study.
Rahaghi FF, Kolaitis NA, Adegunsoye A, de Andrade JA, Flaherty KR, Lancaster LH, Lee JS, Levine DJ, Preston IR, Safdar Z, Saggar R, Sahay S, Scholand MB, Shlobin OA, Zisman DA, Nathan SD.
Chest. 2022 Jul;162(1):145-155. doi: 10.1016/j.chest.2022.02.012. Epub 2022 Feb 15.
Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes.
Nathan SD, Deng C, King CS, DuBrock HM, Elwing J, Rajagopal S, Rischard F, Sahay S, Broderick M, Shen E, Smith P, Tapson VF, Waxman AB.
Chest. 2023 Feb;163(2):398-406. doi: 10.1016/j.chest.2022.09.007. Epub 2022 Sep 15.
Targeting VEGF-A/VEGFR2 Y949 Signaling-Mediated Vascular Permeability Alleviates Hypoxic Pulmonary Hypertension.
Zhou W, Liu K, Zeng L, He J, Gao X, Gu X, Chen X, Jing Li J, Wang M, Wu D, Cai Z, Claesson-Welsh L, Ju R, Wang J, Zhang F, Chen Y.
Circulation. 2022 Dec 13;146(24):1855-1881. doi: 10.1161/CIRCULATIONAHA.122.061900. Epub 2022 Nov 17.
